Henry Schein, Inc. (HSIC) Shares Bought by AMP Capital Investors Ltd

AMP Capital Investors Ltd boosted its position in shares of Henry Schein, Inc. (NASDAQ:HSIC) by 102.5% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 45,126 shares of the company’s stock after acquiring an additional 22,839 shares during the period. AMP Capital Investors Ltd’s holdings in Henry Schein were worth $3,699,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Headinvest LLC increased its holdings in shares of Henry Schein by 107.6% during the 3rd quarter. Headinvest LLC now owns 6,580 shares of the company’s stock worth $517,000 after purchasing an additional 3,410 shares during the period. Allianz Asset Management GmbH increased its holdings in shares of Henry Schein by 147.0% during the 3rd quarter. Allianz Asset Management GmbH now owns 613,004 shares of the company’s stock worth $50,260,000 after purchasing an additional 364,842 shares during the period. Nomura Asset Management Co. Ltd. increased its holdings in shares of Henry Schein by 103.2% during the 3rd quarter. Nomura Asset Management Co. Ltd. now owns 47,172 shares of the company’s stock worth $3,867,000 after purchasing an additional 23,956 shares during the period. King Luther Capital Management Corp increased its holdings in shares of Henry Schein by 104.7% during the 3rd quarter. King Luther Capital Management Corp now owns 6,038 shares of the company’s stock worth $495,000 after purchasing an additional 3,088 shares during the period. Finally, Citizens Financial Group Inc. RI increased its holdings in shares of Henry Schein by 93.3% during the 3rd quarter. Citizens Financial Group Inc. RI now owns 80,498 shares of the company’s stock worth $6,600,000 after purchasing an additional 38,859 shares during the period. 91.75% of the stock is owned by hedge funds and other institutional investors.

Shares of Henry Schein, Inc. (NASDAQ HSIC) opened at $70.16 on Friday. The company has a debt-to-equity ratio of 0.30, a quick ratio of 0.86 and a current ratio of 1.55. The firm has a market cap of $10,781.20, a PE ratio of 19.27, a price-to-earnings-growth ratio of 1.93 and a beta of 0.99. Henry Schein, Inc. has a 52 week low of $65.28 and a 52 week high of $93.50.

Henry Schein (NASDAQ:HSIC) last issued its quarterly earnings data on Monday, November 6th. The company reported $0.87 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.90 by ($0.03). The firm had revenue of $3.16 billion for the quarter, compared to the consensus estimate of $3.05 billion. Henry Schein had a return on equity of 19.71% and a net margin of 4.52%. Henry Schein’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same period in the prior year, the company posted $0.84 earnings per share. sell-side analysts predict that Henry Schein, Inc. will post 3.6 EPS for the current fiscal year.

Henry Schein announced that its Board of Directors has authorized a stock buyback program on Monday, September 18th that permits the company to buyback $400.00 million in outstanding shares. This buyback authorization permits the company to purchase up to 6.3% of its shares through open market purchases. Shares buyback programs are usually a sign that the company’s management believes its shares are undervalued.

HSIC has been the topic of a number of analyst reports. Deutsche Bank initiated coverage on shares of Henry Schein in a research note on Friday, December 8th. They issued a “buy” rating and a $79.00 target price on the stock. Morgan Stanley cut shares of Henry Schein from an “equal weight” rating to an “underweight” rating and set a $88.00 target price on the stock. in a research note on Wednesday, December 6th. Credit Suisse Group reissued a “neutral” rating and issued a $80.00 target price (down previously from $87.50) on shares of Henry Schein in a research note on Tuesday, November 28th. Stephens initiated coverage on shares of Henry Schein in a research note on Tuesday, November 28th. They issued an “equal weight” rating and a $76.00 target price on the stock. Finally, Zacks Investment Research cut shares of Henry Schein from a “hold” rating to a “sell” rating in a research note on Monday, November 13th. Three research analysts have rated the stock with a sell rating, seven have given a hold rating and eight have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $87.79.

In other Henry Schein news, Director Barry J. Alperin sold 5,796 shares of the company’s stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $70.76, for a total transaction of $410,124.96. Following the sale, the director now directly owns 48,172 shares of the company’s stock, valued at $3,408,650.72. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 1.19% of the stock is currently owned by corporate insiders.

TRADEMARK VIOLATION WARNING: This report was posted by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this report on another site, it was copied illegally and republished in violation of United States & international copyright and trademark law. The original version of this report can be viewed at https://sportsperspectives.com/2017/12/17/henry-schein-inc-hsic-shares-bought-by-amp-capital-investors-ltd.html.

Henry Schein Company Profile

Henry Schein, Inc is a provider of healthcare products and services primarily to office-based dental, animal health and medical practitioners. The Company operates through two segments: healthcare distribution, and technology and value-added services. The healthcare distribution segment distributes consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.

Want to see what other hedge funds are holding HSIC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Henry Schein, Inc. (NASDAQ:HSIC).

Institutional Ownership by Quarter for Henry Schein (NASDAQ:HSIC)

Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply